Nektar Therapeutics stock hits 52-week high at 59.72 USD

Nektar Therapeutics stock has reached a significant milestone, hitting a 52-week high of 59.72 USD. According to InvestingPro data, the stock’s technical indicators suggest overbought conditions, with the company now commanding a market capitalization of $1.12 billion. This marks a notable achievement for the company, reflecting a strong performance over the past year. The stock’s ascent is underscored by an impressive 1-year change, with shares appreciating by 228.21%. InvestingPro analysis reveals even more impressive gains, including a 354.56% surge over the past six months, though current valuations suggest the stock may be overvalued. Subscribers can access 12 additional ProTips and a comprehensive Pro Research Report for deeper insights into Nektar’s financial health and growth prospects.

In other recent news, Nektar Therapeutics announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe atopic dermatitis. The drug achieved statistical significance in the primary endpoint of mean improvement in the Eczema Area and Severity Index (EASI) at week 16, with a high dose showing a 61% mean improvement compared to 31% for placebo. Following this, Jefferies raised its price target for Nektar Therapeutics to $99, maintaining a Buy rating due to positive patient-reported outcomes from the Rezpeg oral presentation. Piper Sandler also reiterated an Overweight rating with a $105 price target, focusing on upcoming clinical data expected next year. Additionally, Nektar’s shares rose significantly after Sanofi released disappointing trial data for its atopic dermatitis treatment, with Piper Sandler noting REZPEG’s differentiated profile and competitive potential. These developments highlight the ongoing interest and positive sentiment among analysts regarding Nektar’s therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.